Physician profile
Vikas Malhotra
NPI 1821058496
$58,232.62
in general payments reported to CMS, 2019-2025
89 companies · $6,128 in 2025
The $6,128 reported for 2025 was more than what 76% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $11K · 2021: $9,429 · 2022: $6,128 · 2023: $5,905 · 2024: $8,373 · 2025: $6,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $10K · Food and Beverage: $7,028 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,699 · Honoraria: $1,088 · Education: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,157.50 |
| Food and Beverage | $7,028.14 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,698.95 |
| Honoraria | $1,088.00 |
| Education | $433.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14,496.61 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Pfizer INC. | $6,822.27 | 2019-2025 | |
| Celgene Corporation | $4,720.79 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $3,572.61 | 2019-2025 | Rybrevant, Talvey, Darzalex |
| Abbvie INC. | $3,319.25 | 2019-2025 | |
| Csl Behring | $3,068.59 | 2019-2021 | |
| Beigene USA, INC. | $2,976.66 | 2020-2024 | Brukinsa |
| Epizyme, INC. | $2,567.81 | 2020-2021 | |
| Karyopharm Therapeutics INC. | $2,355.85 | 2020-2023 | Xpovio |
| Coherus Oncology, INC. | $1,088.00 | 2023 | |
| Cti Biopharma Corp. | $1,016.89 | 2022-2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $994.89 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $961.04 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $817.20 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Novartis Pharmaceuticals Corporation | $725.94 | 2019-2025 |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.